CRA’s Andrew Tepperman provided expert testimony in multiple proceedings before the Patented Medicine Prices Review Board (PMPRB) in relation to alleged excessive pricing by pharmaceutical companies in Canada. CRA’s team addressed the application of published guidelines by the PMPRB, and the relationship between certain tests described in those guidelines and other means of evaluation whether drug prices are excessive.
Removing the roadblocks: Policies to improve access to long-acting reversible contraceptives (LARCs)
A variety of contraceptive options exist, each with their own pros and cons. Long-acting reversible contraceptives (LARCs), like IUDs, contraceptive...